28A-1091014
US filing, TW I816286
Hepatocellular carcinoma (HCC) is a malignant cancer. The curative treatments are only applicable at early stages that is hard to be detected or differentiated from liver cirrhosis (LC). The current HCC biomarker is serum alpha-fetoprotein (AFP); however, >30% HCC patients had normal AFP levels. Here, we demonstrated that monomeric serum amyloid A (SAA) and its oligomers are significantly higher in HCC patients than in hepatitis and LC. Monomeric A-SAA differentiates different HCC stages as well as early vs. late stage HCC. Moreover, we can distinguish early stage HCC from LC by a protein misfolding cyclic amplification technique in the low AFP cohorts. Overall, we demonstrated that SAA and its prion-like property facilitate the early diagnosis of HCC, especially in patients with low AFP levels.
- First to differentiate different stages of HCC by a novel serum biomarker SAA
- First to differentiate LC and early stage HCC by a novel serum biomarker SAA
- First to amplify serum SAA level to differentiate LC and early stage HCC, even in low AFP groups
- To use serum SAA level to differentiate LC and HCC
- To use amplified SAA signal in serum to differentiate LC and early stage HCC, even in low AFP groups
- Detecting SAA level in serum to differentiate different stages of HCC
Yun-Ru Chen, Pei-Jer Chen, Tung-Hung Su
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Serum amyloid A as a serum biomarker for differentiation of liver cirrhosis and hepatocellular carcinoma